Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOD2 | Q9HC29 | 2/20 | 0.54 |
| ▸ | NOD1 | Q9Y239 | 2/20 | 0.54 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.52 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.52 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.52 |
| ▸ | KCNK3 | O14649 | 7/20 | 0.51 |
| ▸ | KCNK9 | Q9NPC2 | 7/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.50 |
| ▸ | SLC2A2 | P11168 | 1/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.50 |
| ▸ | F10 | P00742 | 1/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.48 |
| ▸ | NPC1 | O15118 | 1/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
| ▸ | RAB9A | P51151 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1430055 | 0.83 | GABRA1 (0.53) | GABRA1GABRA5GABRB2KCNK3KCNK9 | |
| SCHEMBL1430240 | 0.79 | GABRA1 (0.55) | GABRA1GABRA5GABRB2KCNK3KCNK9 | |
| SCHEMBL6302610 | 0.79 | NOD2 (0.84) | NOD2NOD1SMN1; SMN2F10KDM4E | |
| SCHEMBL1430614 | 0.78 | SLC2A2 (0.77) | GABRA1GABRA5GABRB2KCNK3KCNK9 | |
| SCHEMBL1430125 | 0.78 | MAPT (0.61) | KCNK3KCNK9SMN1; SMN2HTT | |
| SCHEMBL1433237 | 0.78 | KCNK3 (0.54) | GABRA1GABRA5GABRB2KCNK3KCNK9 | |
| SCHEMBL1430941 | 0.76 | GABRA1 (0.47) | GABRA1GABRA5GABRB2KCNK3KCNK9 | |
| SCHEMBL7222041 | 0.76 | SLC2A2 (0.63) | GABRA1GABRA5GABRB2KCNK3KCNK9 | |
| SCHEMBL1430340 | 0.75 | KCNK3 (0.51) | GABRA1GABRA5GABRB2KCNK3KCNK9 | |
| SCHEMBL1430155 | 0.74 | KCNK3 (0.52) | KCNK3KCNK9SMN1; SMN2KDM4ENPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130289013-A1 | IMIDAZO[1,2-a]PYRIDINE COMPOUNDS | SUNOVION PHARMACEUTICALS INC. | 2013-10-31 | — | — | US | disclosed |
| US-8497278-B2 | Imidazo[1,2-a]pyridine compounds | SUNOVION PHARMACEUTICALS INC. (US) | 2013-07-30 | — | — | US | disclosed |
| US-20110166146-A1 | IMIDAZO[1,2-a]PYRIDINE COMPOUNDS | SUNOVION PHARMACEUTICALS INC. (US) | 2011-07-07 | — | — | US | disclosed |
| EP-2300470-A2 | IMIDAZO[1,2-A]PYRIDINE COMPOUNDS AS GABA-A RECEPTOR MODULATORS | Sepracor Inc. (US) | 2011-03-30 | — | — | EP | disclosed |
| WO-2009143156-A2 | IMIDAZO[1,2-a]PYRIDINE COMPOUNDS | SEPRACOR INC. (US) | 2009-11-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110166146-A1 | IMIDAZO[1,2-a]PYRIDINE COMPOUNDS | PAICS, ITPA, DPYD | NOD2 3128/4885NOD1 2437/4885GABRA1 817/4885 |
| US-20130289013-A1 | IMIDAZO[1,2-a]PYRIDINE COMPOUNDS | PAICS, ITPA, DPYD | NOD2 3128/4885NOD1 2437/4885GABRA1 817/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.